Generic Name and Formulations:
Ibutilide fumarate 0.1mg/mL; soln for IV infusion.
Indications for CORVERT:
Rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.
Give by IV infusion over 10 minutes. ≥18yrs: (≥60kg) initially 1mg; (<60kg) initially 0.01mg/kg. If no response, may repeat second 10-minute infusion of equal strength given 10 minutes after first infusion. Discontinue infusion as soon as the presenting arrhythmia has terminated, or if sustained/nonsustained ventricular tachycardia or marked QT prolongation occurs.
<18yrs: not recommended.
Risk of fatal arrhythmias (eg, sustained polymorphic ventricular tachycardia, usually associated with QT prolongation (torsades de pointes), but sometimes without documented QT prolongation may occur. Be experienced with the treatment and monitoring of life-threatening arrhythmias before administering. Have cardiac monitoring equipment and proper medication available. Correct hypokalemia and hypomagnesemia before starting. Monitor ECG continuously for at least 4 hours post infusion or until QTC returned to baseline. Proarrhythmia conditions (eg, ventricular arrhythmias, atrial flutter or fibrillation, QTC intervals >440 msec, hypokalemia, history of CHF, low left ventricular ejection fraction). Previous polymorphic ventricular tachycardia: not recommended. Renal or hepatic dysfunction (monitor). Pregnancy (Cat.C). Nursing mothers: not recommended.
Class III antiarrhythmic.
Class Ia antiarrhythmics (eg, disopyramide, quinidine, procainamide) or other Class III drugs (eg, amiodarone, sotalol): do not give concomitantly or within 4 hours post-infusion. QT prolongation with phenothiazines, tricyclic and tetracyclic antidepressants, H1 receptor antagonists. Caution with digoxin.
Ventricular extrasystoles, sustained or nonsustained polymorphic ventricular tachycardia, sustained monomorphic ventricular tachycardia, headache, hypo- or hypertension, tachycardia, bundle branch block, AV block, nausea, QT segment prolonged, bradycardia.
Single-dose vial (10mL)—1
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Improving the Care of Aging Adults Living With HIV
- Infection Prevention Differs Between Small, Large Hospitals
- International Antiviral Society-USA Updates Recommendations for HIV Treatment and Prevention
- Previous Missed Appointments Predict Likelihood of Trend in Patients With HIV
- FDA Warns Against Long-Term Azithromycin Use for Some
- Identifying the Source of C difficile in Hospitalized Patients
- Antibiotics Often Unnecessary for Sacral Pressure Ulcers Complicated by Osteomyelitis
- Sensitivity and Specificity of 7 Treponemal Tests for Syphilis Diagnosis
- Automated EHR Algorithm More Effective Than Nurse-Driven Protocol for HCV, HIV Screening
- A Pan-Tuberculosis Regimen: The Debate Continues
- HCV Eradication in HIV/HCV-Coinfection Decreases Immune Activation
- Tolerability of Switching to Long-acting Cabotegravir Plus Rilpivirine From Current HIV-1 Regimen
- Time to Blood Culture Positivity Predictive of Mortality in S Aureus Infective Endocarditis
- C difficile Tied to Increased Graft Loss in Solid Organ Recipients
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd